Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Negative regulation of bcl-2 expression by p53 in hematopoietic cells

Oncogene volume 20, pages 240–251 (2001)Cite this article

Abstract

The p53 protein activates promoters containing p53 binding sites, and it represses other promoters. We examined the effect of p53 on bcl-2 expression in both the DHL-4 B cell line and the K562 erythroleukemia line. Transient transfection analyses revealed that wild-type p53 repressed the bcl-2 full-length promoter. The region of the bcl-2 promoter that was responsive to p53 was mapped to the bcl-2 P2 minimal promoter region, and we showed that p53 and the TATA binding protein bound to the bcl-2 TATA sequence. The TATA binding protein, p53, histone deacetylase-1 and mSin3a could be co-immunoprecipitated from K562 cell nuclear extract. The TATA binding protein and mSin3a could be recovered in a complex at the bcl-2 promoter TATA sequence, however, the formation of this complex was not dependent on the presence of p53. Treatment of K562 cells with the histone deacetylase inhibitor, trichostatin A, resulted in an increase in bcl-2 promoter activity whether p53 was present or not. Therefore, we demonstrated that p53 and the histone deacetylases repress the bcl-2 promoter independently. Similar results were obtained when endogenous bcl-2 mRNA or protein levels were measured in response to either p53 or trichostatin A, and p53 expression resulted in enhanced apoptosis. RNase protection assays demonstrated that transcription from the endogenous 3′ bcl-2 promoter was decreased by p53. The regions of p53 that were required for repression of the bcl-2 promoter were defined. We conclude that the TATA sequence in the bcl-2 P2 minimal promoter is the target for repression by p53, and that the interaction between p53 and TBP is most likely responsible for the repression. Mutation of p53 may play a role in the up-regulation of bcl-2 expression in some B cell lymphomas.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9

Similar content being viewed by others

References

  • Aoyama N, Nagase T, Sawazaki T, Mizuguchi G, Nadagoshi H, Fujisawa JI, Yoshida M and Ishii S. . 1992 Proc. Natl. Acad. Sci. USA 89: 5403–5407.

  • Barrans S, Randerson J, Evans P, Blythe D, Shiach C, Child JA, Morgan G and Jack AS. . 1995 Br. J. Haemat. 90: 830–836.

  • Budhram-Mahadeo V, Morris PJ, Smith MD, Midgley CA, Boxer LM and Latchman DS. . 1999 J. Biol. Chem. 274: 15237–15244.

  • Chen H-M and Boxer LM. . 1995 Mol. Cell. Biol. 15: 3840–3847.

  • Chin KV, Ueda K, Pastan I and Gottesman MM. . 1992 Science 255: 459–462.

  • Cleary ML, Smith SD and Sklar J. . 1986 Cell 47: 19–28.

  • Finlay CA, Hinds PW and Levine AJ. . 1989 Cell 57: 1083–1093.

  • Ginsberg D, Mechta F, Yaniv M and Oren M. . 1991 Proc. Natl. Acad. Sci. USA 88: 9979–9983.

  • Gotlieb TM and Oren M. . 1996 Biochim. Biophys. Acta 1287: 77–102.

  • Hassig CA, Fleischer TC, Billin AN, Schreiber SL and Ayer DE. . 1997 Cell 89: 341–347.

  • Heckman CA, Mehew JW, Ying G-G, Introna M, Golay J and Boxer LM. . 2000 J. Biol. Chem. 275: 6499–6508.

  • Horikoshi N, Usheva A, Chen J, Levine AJ, Weinmann R and Shenk T. . 1995 Mol. Cell. Biol. 15: 227–234.

  • Ilyas M, Kendall M, Jalal H, Linton C and Rooney N. . 1996 J. Pathol. 180: 249–253.

  • Ji L, Mochon E, Arcinas M and Boxer LM. . 1996 J. Biol. Chem. 271: 22687–22691.

  • Jin S and Scotto KW. . 1998 Mol. Cell. Biol. 18: 4377–4384.

  • Ko LJ and Prives C. . 1996 Genes Dev. 10: 1054–1072.

  • Kramer MHH, Hermans J, Parker J, Drol ADG, Kluin-Nelemans JC, Haak HL, van Groningen K, van Krieken JHJM, de Jong D and Kluin PM. . 1996 J. Clin. Oncol. 14: 2131–2138.

  • Laherty CD, Yang WM, Sun JM, Davie JR, Seto E and Eisenman RN. . 1997 Cell 89: 349–356.

  • Levine AJ. . 1997 Cell 88: 232–331.

  • Luo RX, Postigo AA and Dean DC. . 1998 Cell 92: 463–473.

  • Mack DH, Vartikar J, Pipas JM and Laimins LA. . 1993 Nature 363: 281–283.

  • Martin DW, Munoz RM, Subler MA and Deb S. . 1993 J. Biol. Chem. 268: 13062–13067.

  • Miyashita T, Harigai M, Hanada M and Reed JC. . 1994a Cancer Res. 54: 3131–3135.

  • Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, Hoffman B and Reed JC. . 1994b Oncogene 9: 1799–1805.

  • Miyashita T and Reed JC. . 1995 Cell 80: 293–299.

  • Moller MB, Nielsen O and Pedersen NT. . 1999 Mod. Pathol. 12: 1010–1016.

  • Murphy M, Ahn J, Walker KK, Hoffman WH, Evans RM, Levine AJ and George DL. . 1999 Genes Dev. 13: 2490–2501.

  • Nguyen PL, Zukerberg LR, Benedict WF and Harris NL. . 1996 Am. J. Clin. Pathol. 105: 538–543.

  • Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T, Tokino T, Taniguchi T and Tanaka N. . 2000 Science 288: 1053–1058.

  • Ryan KM and Vousden KH. . 1998 Mol. Cell. Biol. 18: 3692–3698.

  • Said JW, Barrera R, Shintaku IP, Nakamura H and Koeffler HP. . 1992 Am. J. Pathol. 141: 1343–1348.

  • Sakamuro D, Sabbatini P, White E and Prendergast GC. . 1997 Oncogene 15: 887–898.

  • Sang BC, Chen JY, Minna J and Barbosa MS. . 1994 Oncogene 9: 853–859.

  • Seto E, Usheva A, Zambetti GP, Momand J, Horikoshi N, Weinmann R, Levine AJ and Shenk T. . 1992 Proc. Natl. Acad. Sci. USA 89: 12028–12032.

  • Seto M, Jaeger U, Hockett RD, Graninger W, Bennett S, Goldman P and Korsmeyer SJ. . 1988 EMBO J. 7: 123–131.

  • Shaulian E, Zauberman A, Ginsberg D and Oren M. . 1992 Mol. Cell. Biol. 12: 5581–5592.

  • Shen Y and Shenk T. . 1994 Proc. Natl. Acad. Sci. USA 91: 8940–8944.

  • Shiio Y, Yamamoto T and Yamaguchi N. . 1992 Proc. Natl. Acad. Sci. USA 89: 5206–5210.

  • Smith MD, Ensor EA, Coffin RS, Boxer LM and Latchman DS. . 1998 J. Biol. Chem. 273: 16715–16722.

  • Soini Y, Paakko P, Alavaiddo M and Vahakangas K. . 1992 J. Clin. Pathol. 45: 1011–1014.

  • Subler MA, Martin DW and Deb S. . 1992 J. Virol. 66: 4757–4762.

  • Subler MA, Martin DW and Deb S. . 1994 Oncogene 9: 1351–1359.

  • Takano Y, Saegusa M, Ikenaga MM and Okayasu I. . 1997 Pathol. Int. 47: 90–94.

  • Tsujimoto Y and Croce C. . 1986 Proc. Natl. Acad. Sci. USA 83: 5214–5218.

  • Tsujimoto Y, Gorham J, Cossman J, Jaffe E and Croce CM. . 1985 Science 229: 1390–1393.

  • Venot C, Maratrat M, Dureuil C, Conseiller E, Bracco L and Debussche L. . 1998 EMBO J. 17: 4668–4679.

  • Villeundas R, Piris MA, Orradre JL, Mollejo M, Algara P, Sanchez L, Martinez JC and Martinez P. . 1992 J. Pathol. 166: 235–241.

  • Walker KK and Levine AJ. . 1996 Proc. Natl. Acad. Sci. USA 93: 15335–15340.

  • Wang TT, Hursting SD, Perkins SN and Phang JM. . 1997 Cancer Lett. 116: 61–69.

  • Watanabe T, Ichikawa A, Saito H and Hotta T. . 1996 Leuk. Lymph. 21: 391–397.

  • Wilson BE, Mochon E and Boxer LM. . 1996 Mol. Cell. Biol. 16: 5546–5556.

  • Wong CW and Privalsky ML. . 1998 Mol. Cell. Biol. 18: 5500–5510.

  • Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R and Beach D. . 1993 Nature 366: 701–704.

  • Yang E and Korsmeyer SJ. . 1996 Blood 15: 386–401.

  • Yang WM, Ahn J, Walker KK, Hoffman WH, Evans RM, Levine AJ and George DL. . 1996 Proc. Natl. Acad. Sci. USA 93: 12845–12850.

  • Yew PR and Berk AJ. . 1992 Nature 357: 82–85.

  • Yonish-Rouach E, Deguin V, Zaitchouk T, Breugnot C, Mishal Z, Jenkins JR and May E. . 1995 Oncogene 11: 2197–2205.

  • Yoshida M, Kijima M, Akita M and Beppu T. . 1990 J. Biol. Chem. 265: 13062–13067.

  • Young RL and Korsmeyer SJ. . 1993 Mol. Cell. Biol. 13: 3686–3697.

  • Yunis JJ, Frizzera G, Oken MM, McKenna J, Theologides A and Arnesen M. . 1987 NEJM 316: 79–84.

Download references

Acknowledgements

This work was supported by National Institutes of Health Grant CA56764.

Author information

Authors and Affiliations

  1. Palo Alto Veterans Affairs Medical Center and the Department of Medicine, The Center for Molecular Biology in Medicine, Stanford University School of Medicine, Stanford, 94305-5112, California, CA, USA

    Yu-ling Wu, John W Mehew, Caroline A Heckman, Magdalena Arcinas & Linda M Boxer

Authors
  1. Yu-ling Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John W Mehew
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Caroline A Heckman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Magdalena Arcinas
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Linda M Boxer
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wu, Yl., Mehew, J., Heckman, C. et al. Negative regulation of bcl-2 expression by p53 in hematopoietic cells. Oncogene 20, 240–251 (2001). https://doi.org/10.1038/sj.onc.1204067

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1204067

Keywords

This article is cited by

Search

Advanced search

Quick links